Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GSK Pays $1.2bn For Phase III-Ready MASH Contender

May 14 2025

• By Andrew McConaghie

New GSK sign — • Source: Shutterstock

Related Content

Boston Pharma Plays Catch Up To Akero, 89bio In MASH

Mar 06 2025

Akero The First To Show Fibrosis Improvement In Cirrhotic MASH

Jan 27 2025

NASH Updates: Boston Pharma, Viking Line Up As Serious Competitors

Nov 20 2024

Related Companies

GSK plc

Akero Therapeutics, Inc.

89bio, Inc.

More from Deals

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window